149 related articles for article (PubMed ID: 16154854)
1. Efficacy of imatinib mesylate as maintenance therapy in adults with acute lymphoblastic leukemia in first complete remission.
Potenza L; Luppi M; Riva G; Marasca R; Martinelli S; Torelli G
Haematologica; 2005 Sep; 90(9):1275-7. PubMed ID: 16154854
[TBL] [Abstract][Full Text] [Related]
2. The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Lee S; Kim YJ; Chung NG; Lim J; Lee DG; Kim HJ; Min CK; Lee JW; Min WS; Kim CC
Cancer; 2009 Feb; 115(3):561-70. PubMed ID: 19117346
[TBL] [Abstract][Full Text] [Related]
3. Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy.
Lange T; Bumm T; Otto S; Al-Ali HK; Kovacs I; Krug D; Köhler T; Krahl R; Niederwieser D; Deininger MW
Haematologica; 2004 Jan; 89(1):49-57. PubMed ID: 14754606
[TBL] [Abstract][Full Text] [Related]
4. The achievement of molecular complete remission during treatment with imatinib mesylate correlates with relapse-free survival in bcr/abl-positive acute lymphoid leukemia patients.
Piccaluga PP; Malagola M; Amabile M; Rondoni M; Paolini S; Pane F; Russo D; Visani G; Baccarani M; Martinelli G
Haematologica; 2004 Oct; 89(10):1269-71. PubMed ID: 15477218
[TBL] [Abstract][Full Text] [Related]
5. Treatment of elderly patients with acute lymphoblastic leukemia--evidence for a benefit of imatinib in BCR-ABL positive patients.
Brandwein JM; Gupta V; Wells RA; Schuh AC; Schimmer AD; Lipton JH; Messner HA; Yi QL; Chun K; Kamel-Reid S; Minden MD
Leuk Res; 2005 Dec; 29(12):1381-6. PubMed ID: 15927253
[TBL] [Abstract][Full Text] [Related]
6. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group.
Yanada M; Takeuchi J; Sugiura I; Akiyama H; Usui N; Yagasaki F; Kobayashi T; Ueda Y; Takeuchi M; Miyawaki S; Maruta A; Emi N; Miyazaki Y; Ohtake S; Jinnai I; Matsuo K; Naoe T; Ohno R;
J Clin Oncol; 2006 Jan; 24(3):460-6. PubMed ID: 16344315
[TBL] [Abstract][Full Text] [Related]
7. Acute lymphoblastic leukemia without the Philadelphia chromosome occurring in chronic myelogenous leukemia with the Philadelphia chromosome.
Jin Huh H; Won Huh J; Myong Seong C; Lee M; Soon Chung W
Am J Hematol; 2003 Nov; 74(3):218-20. PubMed ID: 14587058
[TBL] [Abstract][Full Text] [Related]
8. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.
Iacobucci I; Rosti G; Amabile M; Poerio A; Soverini S; Cilloni D; Testoni N; Abruzzese E; Montefusco E; Ottaviani E; Iuliano F; Russo D; Gobbi M; Alimena G; Martino B; Terragna C; Pane F; Saglio G; Baccarani M; Martinelli G
J Clin Oncol; 2006 Jan; 24(3):454-9. PubMed ID: 16421422
[TBL] [Abstract][Full Text] [Related]
9. Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy.
Yanada M; Sugiura I; Takeuchi J; Akiyama H; Maruta A; Ueda Y; Usui N; Yagasaki F; Yujiri T; Takeuchi M; Nishii K; Kimura Y; Miyawaki S; Narimatsu H; Miyazaki Y; Ohtake S; Jinnai I; Matsuo K; Naoe T; Ohno R;
Br J Haematol; 2008 Nov; 143(4):503-10. PubMed ID: 18986386
[TBL] [Abstract][Full Text] [Related]
10. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).
Ottmann OG; Wassmann B; Pfeifer H; Giagounidis A; Stelljes M; Dührsen U; Schmalzing M; Wunderle L; Binckebanck A; Hoelzer D;
Cancer; 2007 May; 109(10):2068-76. PubMed ID: 17429836
[TBL] [Abstract][Full Text] [Related]
11. Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.
Iacobucci I; Saglio G; Rosti G; Testoni N; Pane F; Amabile M; Poerio A; Soverini S; Bassi S; Cilloni D; Bassan R; Breccia M; Lauria F; Izzo B; Merante S; Frassoni F; Paolini S; Montefusco E; Baccarani M; Martinelli G;
Clin Cancer Res; 2006 May; 12(10):3037-42. PubMed ID: 16707599
[TBL] [Abstract][Full Text] [Related]
12. Successful interim therapy with imatinib prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute myeloid leukemia.
Cho BS; Kim HJ; Lee S; Eom KS; Min WS; Lee JW; Kim CC
Eur J Haematol; 2007 Aug; 79(2):170-3. PubMed ID: 17608710
[TBL] [Abstract][Full Text] [Related]
13. Anterior chamber infiltration in a patient with Ph+ acute lymphoblastic leukemia in remission with imatinib.
Hurtado-Sarrió M; Duch-Samper A; Taboada-Esteve J; Martínez-Dominguez JA; Senent-Peris ML; Menezo-Rozalén JL
Am J Ophthalmol; 2005 Apr; 139(4):723-4. PubMed ID: 15808178
[TBL] [Abstract][Full Text] [Related]
14. Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment.
Colombat M; Fort MP; Chollet C; Marit G; Roche C; Preudhomme C; Reiffers J; Praloran V; Mahon FX
Haematologica; 2006 Feb; 91(2):162-8. PubMed ID: 16461299
[TBL] [Abstract][Full Text] [Related]
15. Prediction of risk of disease recurrence by genome-wide cDNA microarray analysis in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy.
Zembutsu H; Yanada M; Hishida A; Katagiri T; Tsuruo T; Sugiura I; Takeuchi J; Usui N; Naoe T; Nakamura Y; Ohno R
Int J Oncol; 2007 Aug; 31(2):313-22. PubMed ID: 17611687
[TBL] [Abstract][Full Text] [Related]
16. Sudden blast crisis in patients with Philadelphia chromosome-positive chronic myeloid leukemia who achieved complete cytogenetic remission after imatinib therapy.
Alimena G; Breccia M; Latagliata R; Carmosino I; Russo E; Biondo F; Diverio D; Mancini M; Nanni M; Mandelli F
Cancer; 2006 Sep; 107(5):1008-13. PubMed ID: 16878324
[TBL] [Abstract][Full Text] [Related]
17. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
Wei Y; Hardling M; Olsson B; Hezaveh R; Ricksten A; Stockelberg D; Wadenvik H
Ann Hematol; 2006 Dec; 85(12):841-7. PubMed ID: 17006667
[TBL] [Abstract][Full Text] [Related]
18. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation.
Weisser M; Tischer J; Schnittger S; Schoch C; Ledderose G; Kolb HJ
Haematologica; 2006 May; 91(5):663-6. PubMed ID: 16627251
[TBL] [Abstract][Full Text] [Related]
19. A randomized multicenter open label phase II study to determine the safety and efficacy of induction therapy with imatinib (Glivec, formerly STI571) in comparison with standard induction chemotherapy in elderly (>55 years) patients with Philadelphia chromosome-positive (Ph+/BCR-ABL+) acute lymphoblastic leukemia (ALL) (CSTI571ADE 10).
Wassmann B; Gökbuget N; Scheuring UJ; Binckebanck A; Reutzel R; Gschaidmeier H; Hoelzer D; Ottmann OG;
Ann Hematol; 2003 Nov; 82(11):716-20. PubMed ID: 14648032
[No Abstract] [Full Text] [Related]
20. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study.
Hess G; Bunjes D; Siegert W; Schwerdtfeger R; Ledderose G; Wassmann B; Kobbe G; Bornhäuser M; Hochhaus A; Ullmann AJ; Kindler T; Haus U; Gschaidmeier H; Huber C; Fischer T
J Clin Oncol; 2005 Oct; 23(30):7583-93. PubMed ID: 16234522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
